about
Immunogenicity of a promiscuous T cell epitope peptide based conjugate vaccine against benzo[a]pyrene: redirecting antibodies to the haptenNovel Anti-Nicotine Vaccine Using a Trimeric Coiled-Coil Hapten CarrierNew directions in nicotine vaccine design and use.Construction of an enantiopure bivalent nicotine vaccine using synthetic peptides.Vaccines against drugs of abuse: where are we now?Cocaine analog coupled to disrupted adenovirus: a vaccine strategy to evoke high-titer immunity against addictive drugs.Novel cocaine vaccine linked to a disrupted adenovirus gene transfer vector blocks cocaine psychostimulant and reinforcing effectsA novel and efficient nicotine vaccine using nano-lipoplex as a delivery vehicleEffect of a nicotine vaccine on nicotine binding to β2*-nicotinic acetylcholine receptors in vivo in human tobacco smokers.High immunogenicity of nicotine vaccines obtained by intradermal delivery with safe adjuvants.Scientific overview: 2013 BBC plenary symposium on tobacco addiction.Impact of distinct chemical structures for the development of a methamphetamine vaccineTargeting nicotine addiction: the possibility of a therapeutic vaccine.Selection of a novel anti-nicotine vaccine: influence of antigen design on antibody function in miceImmunogenicity of individual vaccine components in a bivalent nicotine vaccine differ according to vaccine formulation and administration conditionsAdjuvants for vaccines to drugs of abuse and addiction.An oxycodone conjugate vaccine elicits drug-specific antibodies that reduce oxycodone distribution to brain and hot-plate analgesia.Enhanced attenuation of nicotine discrimination in rats by combining nicotine-specific antibodies with a nicotinic receptor antagonistEnhancing nicotine vaccine immunogenicity with liposomes.Optimization of a methamphetamine conjugate vaccine for antibody production in miceNicotine vaccines to assist with smoking cessation: current status of research.Immunopharmacotherapy: vaccination strategies as a treatment for drug abuse and dependence.Anti-drug vaccines to treat substance abuse.Nicotine conjugate vaccine as a novel approach to smoking cessation.Nicotine vaccines to treat tobacco dependence.Conjugate Vaccine Immunotherapy for Substance Use Disorder.Hapten-specific naïve B cells are biomarkers of vaccine efficacy against drugs of abuse.A simple physiologically based pharmacokinetic model evaluating the effect of anti-nicotine antibodies on nicotine disposition in the brains of rats and humans.Increased efficacy of a trivalent nicotine vaccine compared to a dose-matched monovalent vaccine when formulated with alumStructurally distinct nicotine immunogens elicit antibodies with non-overlapping specificities.Vaccination against nicotine alters the distribution of nicotine delivered via cigarette smoke inhalation to rats.The next-generation nicotine vaccine: a novel and potent hybrid nanoparticle-based nicotine vaccine.A nanoparticle-based nicotine vaccine and the influence of particle size on its immunogenicity and efficacy.Engineering of a hybrid nanoparticle-based nicotine nanovaccine as a next-generation immunotherapeutic strategy against nicotine addiction: A focus on hapten density.Rationalization of a nanoparticle-based nicotine nanovaccine as an effective next-generation nicotine vaccine: A focus on hapten localization.
P2860
Q28483992-93ADA23B-B06F-459F-9D7C-6572C0BA0492Q28542642-FAAA12E7-8AD3-464E-B354-604753D5F822Q33719424-A0CB8436-179A-4F6E-B391-EBB1E9467910Q33751968-71C11FB3-98F2-4C1C-8603-6323DEFEED0CQ33776777-CAAA1689-CCC6-4469-A3DB-98FB5DAB9CEDQ34157554-2AF25C2A-55C2-4190-BAD7-68DECFF311C2Q34216479-A8DEDA9C-B804-497D-8CA5-8CAF14169729Q34271517-8768148E-BBAF-4480-88EE-A85463E4A34EQ34329011-382D3E9A-C20E-493D-9164-2DDDD6A08539Q34466125-AB054971-8B69-4234-9641-D24494EE92D7Q34487271-73D753D5-095B-4797-80DC-8C8AA1D80AF9Q34956542-1E492B94-94C8-46BD-8EC2-AFA4F6730134Q34987300-4FA6B91D-1278-4A03-9FFC-2E0C2985D547Q35009554-77D73897-5044-41C8-969F-3E155C80F40AQ35061547-9DF95D8B-8592-40C0-B642-EAD4886E2AA3Q35493923-2E22C810-F510-4E73-9267-6AAEBA848521Q35847661-9379D354-8DBA-4BA8-8B94-4FAB29BA1957Q35975765-C32F324B-0578-4133-8E76-5F356762988FQ36569318-E642C9A7-E334-40C3-BB21-AB4EFF8A43BFQ36854009-68BAEE02-BE2E-4F6A-B525-0964E42F8B24Q36987118-18F73AE2-E9D6-461A-8753-B5B039C7094AQ37401384-901AEE06-7341-4417-A8A9-B35CD0572017Q37427396-FC3FBDBD-E88B-49F1-BD58-49E7573B1B2AQ37933382-FAD12192-01EB-4669-8702-3068AF1E6E54Q38056382-C35C87E3-496A-43C8-99D6-E145C2AF414FQ39387013-18B42975-D991-4CCE-B7FD-07451E0D784FQ39519649-A9387DA3-478A-4EDE-92EF-66B2370ACF77Q39544975-CD441410-46AB-4CDF-8160-1B83D1FBD1D8Q39556344-AB7DA6DF-6078-4F77-A1CD-05CE62515649Q40431126-51BD00BC-6B7C-4F0C-BA0B-88465E7C912FQ41959328-ACAC636F-25D6-4D03-BEA8-81A4240C8796Q42627924-C9B3DF5E-F2C0-4767-984E-C9F480D21F45Q45040238-EA9CD066-C566-4C7B-B7FC-BB4F4353FDCCQ45052268-EB0D9FFF-E1F6-4434-837D-09E4B99A0979Q45060078-512548EB-D087-4C87-A1F6-FB05C53828CF
P2860
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Enhanced immunogenicity of a bivalent nicotine vaccine
@en
Enhanced immunogenicity of a bivalent nicotine vaccine
@nl
type
label
Enhanced immunogenicity of a bivalent nicotine vaccine
@en
Enhanced immunogenicity of a bivalent nicotine vaccine
@nl
prefLabel
Enhanced immunogenicity of a bivalent nicotine vaccine
@en
Enhanced immunogenicity of a bivalent nicotine vaccine
@nl
P2093
P2860
P1476
Enhanced immunogenicity of a bivalent nicotine vaccine
@en
P2093
C A Earley
D E Keyler
M P Murtaugh
P R Pentel
P2860
P304
P356
10.1016/J.INTIMP.2008.07.001
P577
2008-07-24T00:00:00Z